摘要
丙肝是一种全球流行性疾病,是导致慢性肝病和肝细胞癌的主要原因之一。近年来,国际上对丙肝的治疗方法发生了巨大变化,干扰素、利巴韦林联合蛋白酶抑制剂的三联治疗方案已成为国际上治疗丙肝的标准用药方案。不仅如此,一些基于新机制的抗丙肝药物也开始涌现出来,如:第二代直接抗病毒药物和靶向宿主的抗病毒药物。这些新药的出现为丙肝患者带来了新的希望,也为我国抗丙肝药物的开发提供了新思路。
Hepatitis C virus is a kind of global epidemic disease and a primary cause of chronic liver disease and hepatocellular carcinoma. The years, the treatment of hepatitis C undergo a enormous change. The triple therapy consisted of interferon,ribavirin and protease inhibitor has became the standard scheme for hepatitis C in national.What＇s more, some anti-HCV drugs with new mechanism have arisen in the market, such as second-generation direct antiviral drugs and antiviral drugs targeting the host. The presence of these new antiviral drugsnot only bring fresh hope to millions of sufferers, but also offer new idea to the research ofanti-HCV drugs in our country.
出处
《临床药物治疗杂志》
2015年第6期1-5,共5页
Clinical Medication Journal
基金
中国博士后科学基金面上项目(2015M572756)
